mouse anti erbb2  (Santa Cruz Biotechnology)

Journal: Molecular Therapy Oncology

Article Title: Lentiviral-mediated panErbB CAR-T cell therapy against head and neck squamous cell carcinomas for patients with Fanconi anemia

doi: 10.1016/j.omton.2025.201060

Figure Lengend Snippet: Analysis of the membrane expression of ErbB1, ErbB2, ErbB3, and ErbB4 molecules in FA-proficient and FA-deficient HNSCC cell lines Left and right axes represent, respectively, the percentage of ErbB positive cells and the specific fluorescence intensity (SFI) corresponding to each ErbB receptor. (A) FA-proficient HNSCCs cell lines. (B) FA-deficient HNSCCs cell lines. SFI expression levels of the different ErbB members were obtained as the ratio between the mean fluorescence intensity (MFI) after staining with the corresponding monoclonal antibody (MoAb) relative to MFI obtained with the control isotype. Bars show the mean ± SEM ( n = 3). (C) Representative flow cytometry analysis of ErbB1-ErbB4 receptors in HNSCCs (VU-1131). FA-A and FA-C represent FA complementation groups with mutations in FANCA and FANCC, respectively.

Article Snippet: Primary antibodies used were anti-EGFR monoclonal antibody (no. 4267, Cell Signaling, 1:20) and anti-Erbb2 monoclonal antibody (no. UMAB36, Origene, 1:20).

Techniques: Membrane, Expressing, Fluorescence, Staining, Control, Flow Cytometry